TUS scientists identify mefloquine as a promising drug against COVID-19

0
251
With a new breakthrough in research on antiviral drugs against SARS-CoV-2, the finish line may finally be in sight in the race to find an effective treatment for COVID-19 | CDC on Pexels

In the fight against COVID-19, scientists have been scanning their arsenals of previously used drugs in hopes of finding any that can be used to treat the disease. One of the contenders under scrutiny, an anti-malarial drug called mefloquine shows great promise, according to a new breakthrough study by a team of Japanese scientists, perhaps giving us a better fighting chance.

In a breakthrough study, a team of scientists—comprising Dr. Koichi Watashi, Kaho Shionoya, Masako Yamasaki, Dr. Hirofumi Ohashi, Dr. Shin Aoki, Dr. Kouji Kuramochi, and Dr. Tomohiro Tanaka from Tokyo University of Science (along with scientists from the National Institute of Infectious Diseases, Kyushu University, The University of Tokyo, Kyoto University, Japanese Foundation for Cancer Research, and Science Groove Inc.)—have identified an anti-malarial drug, mefloquine (which is incidentally a derivative of hydrochloroquine), that is effective against SARS-CoV-2. Their findings are published
in Frontiers in Microbiology.

Detailing their modus operandi, lead scientist in the team Dr. Watashi says, “To identify drugs with higher antiviral potency than existing antivirals, we first screened approved
anti-parasitic/anti-protozoal drugs. We found that mefloquine had the highest anti-SARS-CoV-2 activity among the tested compounds. Upon testing it against other quinoline derivatives, such as hydrochloroquine, in a cell line mimicking the cell-based environments of human lung cells, we found it to be better.”

The team further explored mefloquine’s mechanism of action. Dr. Watashi explains the process, “In our cell assays, mefloquine readily reduced the viral RNA levels when applied at the viral entry phase but showed no activity during virus-cell attachment. This shows that mefloquine is effective on SARS-COV-2 entry into cells after attachment on cell
surface.”

Thus, to bolster mefloquine’s anti-viral activity, the scientists looked into the possibility of combining it with a drug that inhibits the replication step of SARS-CoV-2: Nelfinavir. Interestingly, they observed that the two drugs acted in “synergy” and the drug combination showed greater anti-viral activity than either showed alone, without being toxic to the cells in the cell lines themselves.

The scientists also mathematically modelled the effectiveness of mefloquine to predict its potential real-world impact if applied to treat COVID-19. What they predicted was that mefloquine could reduce the overall viral load in affected patients to under 7% and shorten the ‘time-till-virus-elimination’ by 6.1 days.

This study must of course be succeeded by clinical trials, but the world can hope that mefloquine becomes a drug used to effectively treat patients with COVID-19.